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Abstract
Rationale There are no recent reports summarising the magnitude of prospective memory (PM) impairments in recreational drug
users.
Objective We performed a meta-analysis of studies (with a parallel group design) examining PM performance in users of
common recreational drugs (including alcohol and tobacco) who were not intoxicated during testing. Studies were also evaluated
for the presence of methodological bias.
Methods Twenty-seven studies were included in the meta-analysis following literature searches of MEDLINE, EMBASE and
PsycINFO. Effect sizes (standardised mean difference; SMD) were calculated separately for the effects of alcohol, cannabis,
ecstasy, methamphetamine and tobacco use. The influences of drug use and study characteristics on effect sizes were explored
using meta-regressions. Sources of study bias were also assessed.
Results Heavy drinkers and regular drug users tended to perform worse than controls on event and time-based PM tasks. Effect
sizes (standardised mean differences; SMDs) for event-based PM impairment across the different drug-using groups/heavy
drinkers ranged between − 1.10 and − 0.49, with no 95% CI crossing 0.00. SMDs for time-based PM ranged between − 0.98
and − 0.70. Except for the CIs associated with the ES for smokers’ time-based PM performance, no CIs crossed 0.00.
Conclusions Although all drug-using groups showed moderate-large impairments in event and time-based PM, effect sizes had
low precision and moderate-high levels of heterogeneity. In addition, several methodological and reporting issues were identified
in the majority of studies. As such, considerable uncertainty remains regarding the role of confounds and the magnitude of PM
impairments in non-intoxicated recreational drug users.
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Introduction
The maladaptive use of recreational substances is a major
international public health concern. Regular and/or excessive
substance use including heavy drinking and smoking is asso-
ciated with significant levels of mortality, morbidity and social
problems, with tobacco and alcohol use being two of the lead-
ing risk factors for disability and mortality (World Health
Organization 2009). Most psychoactive compounds are neu-
rotoxic, especially after large or repeated doses, and in the case
of illicit drugs, often contain adulterants with unknown asso-
ciated toxicity. As such, impairments in cognitive functioning
following acute or chronic drug use (Fernández-Serrano et al.
2011) and consequent interference with daily activities
(Grafman and Litvan 1999) is perhaps unsurprising. One do-
main of special relevance to everyday functioning, for which
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there is mounting experimental evidence of drug-induced im-
pairments, is prospective memory (PM).
PM refers to the ability to remember to carry out intended
actions in the future (Brandimonte et al. 1996). According to
McDaniel and Einstein’s (2000) multi-process model, PM relies
on either spontaneous retrieval (in which the occurrence of a
triggering event promotes retrieval of the intended action from
long-term memory) or strategic monitoring (in which the partic-
ipant actively monitors the environment for triggering cues).
When cognitive processes involved in on-going behaviour sup-
port the processes involved in PM, the tasks are defined as ‘focal-
cue’ tasks and are thought to rely on spontaneous retrieval.
Alternatively, when these do not support the processes involved
in PM, the relevant tasks are defined as ‘non-focal’ and depend
upon strategic monitoring. In addition, a distinction is made be-
tween event- and time-based PM tasks with the former relying
more on spontaneous, cue-driven retrieval and the latter on stra-
tegic monitoring (Einstein et al. 1995). Whilst event-based tasks
require participants to perform an intention in response to an
external cue (e.g. Bbuy a birthday present at the shopping
centre^), time-based tasks require participants to perform an in-
tention at a specific time or after a delay (e.g. call the plumber at
2 pm).
Severe impairments in PM likely have commensurately se-
vere consequences for daily functioning through a failure to enact
intended (adaptive) actions. In those individuals who are
attempting to refrain from drug use, PM impairments may also
interfere with the ability to apply planned relapse prevention
strategies. However, while the negative consequences of psycho-
active drug use on PM are commonly reported, methodological
limitations in a significant amount of existing research mean that
the nature and severity of PM problems that are attributable to
specific drugs remains unclear.
Subjective measures of meta-cognition suggest impair-
ments in PM amongst heavy drinkers (Heffernan et al. 2002;
Ling et al. 2003, 2010), cannabis users (Montgomery and Fisk
2007; Fisk and Montgomery 2008) and ecstasy users
(Heffernan et al. 2001a, b; Rodgers et al. 2001, 2003;
Hadjiefthyvoulou et al. 2010). However, the self-report mea-
sures used to investigate these metacognitive effects may be
susceptible to biases related to lifestyle (Uttl and Kibreab
2011), anxiety (Bedi and Redman 2008a), retrospective mem-
ory (Brown and Craik 2000) and social acquiescence (Ling
et al. 2010). Furthermore, self-reported complaints about PM
have limited predictive validity and are, at best, only weakly
correlated with performance on everyday PM-dependent tasks
(Hertzog et al. 2000).
In light of these measurement issues, some studies have
investigated drug effects on PM with behavioural rather than
self-report measures. Similar to the above findings, these stud-
ies have shown, for example, that acute intoxication from
alcohol (Leitz et al. 2009; Montgomery et al. 2011;
Paraskevaides et al. 2010) and ecstasy (Kuypers et al. 2013;
Ramaekers et al. 2009; van Wel et al. 2011) adversely affects
PM abilities. However, there are likely substantial differences
between the pharmacological effects and pharmacokinetic
profiles of single doses of pharmaceutical-grade compounds
administered in laboratory settings and those used
recreationally in naturalistic contexts. Thus, while lab-based
acute drug studies enable tight experimental control, they pro-
vide little insight into whether PM deficits extend beyond the
acutely or sub-acutely intoxicated state.
In this study, we therefore use a meta-analytic approach to
review the chronic effects of psychoactive drugs on PM in
non-intoxicated users. In addition to determining effect sizes
of PM impairment, reviewed studies were also assessed for
susceptibility to bias and effects of important confounds such
as premorbid intelligence and age (Cherry and LeCompte
1999).We focus on the effects of licit and illicit drugs on event
and time-based PM performance.
Method
Search methods
Articles were identified through a literature search of
MEDLINE (1946 to March 2017), EMBASE (1980 to
March 2017) and PsycINFO (1806 to March 2017), using
keywords and synonyms of the following common categories
of licit and illicit recreational drugs: ‘alcohol’ OR ‘cannabis’
OR ‘tobacco’ OR ‘amphetamine’ OR ‘cocaine’ OR ‘opioid.’
The ‘AND’ operator was used for the keyword: ‘prospective
memory’ (see supplementary material for search strategy: S1).
‘Binge drink?’ was included as an additional alcohol-specific
search term. Electronic searches were supplemented by hand
searches of reference lists, although this yielded no additional
studies.
Studies were included if they were full-text journal articles
and met the following criteria: (1) were published in an
English language peer-reviewed journal, (2) the primary aim
was to examine the effects of psychoactive drug-use on PM
performance, (3) used a parallel group design with a control
condition (consisting of non-using or light and/or infrequent
users) and experimental condition (participants who frequent-
ly and/or excessively used the primary drug), (4) evaluated
PM using a behavioural rather than self-report measure and
(5) used a behavioural task that tapped the full complement of
cognitive activities required for PM (see below). The process
of study selection and exclusion followed PRISMAguidelines
(Fig. 1).
Inclusion criteria for prospective memory tasks
According to influential conceptual models of the cognitive
processes involved in successful PM performance, there are
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four sequential stages in the execution of an intended future
action (e.g. Knight 1998). The initial stage involves the for-
mation and encoding of an intention and action plan as well as
an evaluation of potential factors that could optimise or im-
pede performance. Secondly, there is a retention interval
where other cognitive activities can potentially interfere with
the rehearsal of the encoded intention. The third stage involves
self-initiated retrieval of the intention, where a target cue trig-
gers the effortful and controlled search for the intention in
memory. Finally, actual retrieval and execution of the inten-
tion occurs. These features of PM require that valid objective
measures of PM incorporate the constituent cognitive process-
es or activities of these four stages. In particular, PM tasks
should incorporate a delay between the encoding and execu-
tion of the intention with the delay filled with a secondary on-
going task. Furthermore the task must incorporate cues or
prompts to initiate intention retrieval without external re-
minders. For the current review, tasks that did not incorporate
all of these features were not considered to be construct-valid
assessments of the full range of PM competencies, and studies
using such tasks were therefore not included.
Data extraction
Quantitative data (mean, standard deviation and sample size)
on PM task performance were extracted and coded by PM
type (event vs. time) by the first and second authors.
Table 1 outlines salient participants and study characteristics
extracted from included studies. We also determined whether
reliability and validity of PM tasks had been formally established
and rated the tasks accordingly (see below). These ratings were
used in a moderator analysis. Fifteen distinct tasks were used to
assess prospective memory across the included studies (Table 1).
These were the Cambridge Prospective Memory Test
(CAMPROMPT; Wilson et al. 2005), Video-Based Prospective
Memory Task (V-B PMT; Titov and Knight 2001), Memory for
Intentions Screening Test (MIST; Raskin et al. 2010), belonging
subtest of the Rivermead Behavioural Memory Test (RBMT;
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Table 1 Demographic and study details by drug group
Experimental Control Prospective memory measure Drug use
Study Subgroups Male:Female Age
mean(SD)
Male:Female Age
mean(SD)
Name Event or
time
Measure
quality
Lifetime
dosage
Alcohol
Griffiths et al. (2012) None 16/8 42.00
(8.74)
16/8 41.90 (8.63) VW Event and
time
1 3
Heffernan et al.
(2010a)
None 7/14 18.70
(0.46)
5/24 18.60 (0.48) PRVP Event 2 2
Heffernan and
O’Neill (2012)
None 14/14 24.10
(5.30)
12/16 24.30 (5.45) CAMPROMPT Event and
time
2 2
Marshall et al. (2016) None 15/25 22.30
(4.10)
6/19 22.55 (4.16) CAMPROMPT Event and
time
2 2
Laloyaux et al.
(2012)
None 17/3 46.0
(10.72)
17/3 45.8 (10.63) CST Event 3 3
Platt et al. (2016) None 11/8 25.55
(2.36)
13/5 27.60 (1.59) VW Event and
time
1 2
Weinborn et al.
(2011)
None 9/12 19.50
(2.10)
11/20 19.70 (1.6) MIST Event and
time
1 1
Cannabis
Bartholomew et al.
(2010)
None 20/25 Not
report-
ed
17/28 Not reported V-B PMT Event 2 2
Bedi and Redman
(2008b)
None 26/22 21.70
(3.50)
21/19 23.10 (3.70) DC Event 3 2
Cuttler et al. (2012) Experimental/ 19/29 20.75
(2.78)
10/38 19.71 (2.59) FT Event 2 1
Chronic users 25/23 20.42
(2.52)
Gallagher et al.
(2014)
None 17/21 21.47
(3.00)
17/48 20.64 (2.23) PRPMT and
FTBPT
Event and
time
3 2
Hadjiefthyvoulou
et al. (2011b)
None 5/7 21.92
(1.56)
2/16 20.44 (2.28) CAMPROMPT Event and
time
2 2
McHale and Hunt
(2008)
None 10/8 21.60
(1.10)
10/10 21.40 (1.60) SIPMT and long
interval
Event and
time
3 ?
Montgomery et al.
(2012)
None 13/7 21.05
(1.79)
7/13 20.30 (4.65) JAAMT Event and
time
3 3
Ecstasy/MDMA
Bedi and Redman
(2008a, b)
None 24/21 22.80
(3.0)
21/19 23.10 (3.70) DC Event 3 2
Gallagher et al.
(2014)
None 51/51 21.85
(2.98)
17/48 20.64 (2.23) PRPMT and
FTBPT
Event and
time
3 2
Hadjiefthyvoulou
et al. (2011a)
None 14/28 21.67
(3.61)
5/26 21.03 (3.25) Belonging test
of RBMT
Event 1 3
Hadjiefthyvoulou
et al. (2011b)
None 17/12 21.17
(1.79)
2/16 20.44 (2.28) CAMPROMPT Event and
time
2 3
Montgomery
et al. (2010)
None 13/10 23.22
(4.56)
9/17 21.92 (2.27) JAAMT Event and
time
3 2
Rendell et al. (2007) None 14/13 21.30
(1.96)
15/19 20.60 (1.40) VW Event and
time
1 ?
Weinborn et al.
(2011)
None 12/19 21.40
(3.30)
11/20 19.70 (1.60) MIST Event and
time
1 1
Zakzanis et al. (2003) None 12/3 24.10
(5.60)
14/3 23.40 (2.00) Belonging test
of RBMT
Event 1 2
Methamphetamine
Iudicello et al. (2011) None 36/3 41.60
(8.80)
11/15 40.60(13.80) MIST Event and
time
1 2
Rendell et al. (2009) None 12/8 27.50
(5.21)
12/8 28.20 (5.00) VW Event and
time
1 2
Tobacco
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Wilson et al. 1985), Six Elements Test (SET; Kliegel et al. 2007),
Designated Crosses Test (DC; Bedi and Redman 2008b), Virtual
Week (VW; Rendell and Craik 2000), Fruit Test (FT; Cuttler
et al. 2012), Pattern Test (Hadjiefthyvoulou et al. 2010), Pattern
Recognition Prospective Memory Task (PRPMT; Gallagher
et al. 2014), Fatigue Time-Based Prospective Memory Test
(FTBPT; Gallagher et al. 2014), Computerised Shopping Task
(CDT; Laloyaux et al. 2012), Short-Interval ProspectiveMemory
Task (SIPMT; McHale and Hunt 2008), Jansari-Agnew-
Akesson-Murphy Task (JAAMT; Jansari et al. 2014) and
Prospective Remembering Video Procedure (PRVP; Seed et al.
2005). Ratings of ‘established psychometric properties’ were
based on previously reported psychometric properties of the tasks
(see S4) using a 1–3 scale (1 =measures with acceptable test-
retest reliability and concurrent validity; 2 = concurrent validity
(objective measures) and questionable or no evidence of test-
retest reliability or split-half reliability, and 3 = no evidence of
reliability and where concurrent validity was based on self-
report measures). In four studies, the Virtual Week was used to
assess prospective memory which makes a distinction between
‘regular’ and ‘irregular’PM tasks (Griffiths et al. 2012; Platt et al.
2016; Rendell et al. 2007, 2009). Here, we only extracted partic-
ipants’ ‘irregular’ PMperformance as the task demands are com-
parable with other measures of PM.
In addition, estimated lifetime drug/alcohol dose was deter-
mined from available information in each study. Within sub-
group, z-scores were calculated. Participant samples were then
rated as 1 = low (<− 1SD), 2 =moderate (− 1 to 1 SD), and 3 =
high (> 1 SD) lifetime exposure to a specific drug. There was no
relevant data to estimate lifetime dose in two studies (McHale
and Hunt 2008; Rendell et al. 2007).
Study quality rating
We also rated studies on robustness of design and susceptibility
to bias (rating was conducted independently by the first two
authors; disagreements in ratings were resolved through discus-
sion). Bias in participant selection, case definition (i.e. allocation
Table 1 (continued)
Experimental Control Prospective memory measure Drug use
Study Subgroups Male:Female Age
mean(SD)
Male:Female Age
mean(SD)
Name Event or
time
Measure
quality
Lifetime
dosage
Behrendt et al. (2015) None 14/9 25.30
(4.26)
8/12 21.80 (2.63) SET Event 3 2
Heffernan et al.
(2010b)
None 5/13 25.20
(5.28)
3/19 22.50 (4.21) CAMPROMPT Event and
time
2 2
Heffernan et al.
(2012)
Smoker 11/16 22.40
(5.13)
3/21 19.00 (2.22) RWPMT Event
Previous
Smoker
3/15 23.70
(5.99)
3 2
Heffernan et al.
(2013)
Second-Hand 13/14 22.00
(1.46)
10/18 22.80 (6.03) CAMPROMPT Event and
time
Current
Smoker
12/12 24.4
(4.79)
Heffernan et al.
(2013)
None 14/25 21.10
(2.63)
18/21 20.60 (2.10) V-B PMT Event 2 2
Heffernan et al.
(2014a)
None 18/6 21.20
(2.04)
14/10 20.50 (0.97) CAMPROMPT Event and
time
2 2
Jansari et al. 2013 None 15/21 27.73
(8.27)
18/18 28.94
(11.50)
JAAMT Event 3 2
McHale and Hunt
(2008)
None 10/10 21.20
(1.28)
10/10 21.40 (1.60) SIPMT Event 3 ?
Marshall et al. (2016) None 6/14 27.15
(6.80)
6/19 No report CAMPROMPT Event and
time
2 2
Opiates
Terrett et al. (2014) 18/8 38.31
(7.46)
16/14 39.47 (7.94) VW Event and
time
1 1
Notes: Cambridge ProspectiveMemory Test (CAMPROMPT;Wilson et al. 2005), Video-Based ProspectiveMemory Task (V-B PMT; Titov and Knight
2001), Memory for Intentions Screening Test (MIST; Raskin et al. 2010), belonging subtest of the Rivermead Behavioural Memory Test (RBMT;Wilson
et al. 1985), Six Elements Test (SET; Kliegel et al. 2007), Designated Crosses Test (DC; Bedi and Redman 2008b), VirtualWeek (VW; Rendell and Craik
2000), Fruit Test (FT; Cuttler et al. 2012), Pattern Test (Hadjiefthyvoulou et al. 2010), Pattern Recognition Prospective Memory Task (PRPMT;
Gallagher et al. 2014), Fatigue Time-Based Prospective Memory Test (FTBPT; Gallagher et al. 2014), Computerised Shopping Task (CDT; Laloyaux
et al. 2012), Short-Interval Prospective Memory Task (SIPMT; McHale and Hunt 2008), Jansari-Agnew-Akesson-Murphy Task (JAAMT; Jansari et al.
2004), and Prospective Remembering Video Procedure (PRVP; Seed et al. 2005)
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to groups based on objective/standardised measures of drug-use)
and blinding of participants and investigators was assessed
(Downs and Black 1998; Sanderson et al. 2007; Wells et al.
2011). Additional items on methodological quality on domains
considered by the authors to be especially relevant for drug stud-
ies of PM were also included in the quality rating scheme
(matching of groups on age, intelligence, drug-use and verifica-
tion of non-intoxication). All domains of bias were assigned a
high, low or unclear risk of bias. If information was not available
in the publication, quality items were coded as ‘not available.’
Details on criteria for quality ratings and a summary of the au-
thors’ judgements about each risk of bias item for each included
study are included in the supplementary section (S2 and S3).
Analyses
Effect sizes based on the standardised mean difference (SMD)
between control and drug-using groups were calculated using
random effects models. Larger negative effect sizes indicated that
the mean performance of the substance-using group was lower
than the control group. Effect sizes in the range 0.20–0.49 were
defined as small, 0.50–0.79 as moderate and ≥ 0.80 as large
(Cohen 1988).
Analyses were conducted using the Cochrane Collaboration’s
ReviewManager software (RevMan version 5.3), and inR using
themetafor package (Viechtbauer 2010). Random effects models
(maximum likelihood estimator) were used, with the assumption
that studies had different true effect sizes, as such the combined
effect size represents a distribution of effect sizes (Higgins and
Green 2011). Heterogeneity was assessed using a point estimate
of the amongst-study variance of true effects (τ2) and the approx-
imate proportion of total variability (I2), where an I2 of 25%, 50%
and 75% is considered small, moderate and large, respectively
(Higgins 2008). When moderate or high heterogeneity was ob-
served, interpretation emphasised the range of likely combined
effect sizes (confidence intervals) rather than a single-summary
effect size. Sensitivity analysis involved stepwise removal of
studies to assess the impact of their removal on high levels of
heterogeneity.
Random effects meta-regressions (maximum likelihood es-
timator) were conducted to relate the effect sizes to character-
istics of the studies (lifetime dosage and measures used). This
form of analysis can help to explain the heterogeneity between
studies providing estimates of the difference in effect between
studies rated on the three levels of each categorical moderator
variable. Due to the number of studies, it was not possible to
conduct analyses on specific drug groups.
Results
Twenty-seven studies fulfilled inclusion criteria and provided
data for meta-analyses. Figure 2 summarises risk of bias rat-
ings for all included studies. Certain methodological features
were consistently rated as having a high risk of bias (e.g.
population sourcing; case definition). For other features (e.g.
blinding of experimenters and participants), reporting was
poor (unclear bias). Alternatively, a number of study features
were less commonly associated with bias across the studies as
a whole (comparability of control and drug-using groups in
terms of participant age, intelligence and alcohol use).
Forest plots for event and time-based PM comparisons are
displayed in Figs. 3 and 4. Means, standard deviations and
Fig. 2 Risk of bias summary:
Prevalence of bias for each
domain presented as percentage
of studies with high, low or
unclear risk of bias
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sample sizes used in effect size calculations are included in the
supplementary material (S5 and S6).
Alcohol
Seven studies compared heavy drinkers (total n = 172), with
an estimated total lifetime use ranging between 800 and
20,000 units, with control groups (total n = 148) on event-
based PM performance. As indicated in Fig. 3, alcohol groups
performed worse than control groups and the true effect size
lays in the small to large range. There was a moderate degree
of heterogeneity (τ2 = 0.164, I2 = 62%) although no individual
study’s removal appreciably reduced heterogeneity.
Of the seven alcohol studies, five also compared heavy
drinkers (total n = 131) with control groups (total n = 99) on
time-based PM (Fig. 4). Again, alcohol groups performed worse
than controls, with the true effect ranging from approximately
zero to large. There was a high level of heterogeneity (τ2 = 0.7,
I2= 87%). However, a single study (Platt et al. 2016) appeared to
disproportionately contribute to heterogeneity. Its removal not
only eliminated heterogeneity (τ2 = 0, I2 = 0%), but also reduced
the overall effect size from SMD=− 0.84 (95% CI; − 1.70 to −
0.02) to − 0.43 (95% CI; − 0.72 to − 0.13).
Cannabis
Six studies compared cannabis users (total n = 205) with an esti-
mated total lifetime use ranging between 312 and 10,699 joints,
with healthy controls (total n = 151), on event-based PM tasks,
with cannabis groups performingworse, and the likely true effect
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size between negligible and large. Accordingly, there was high
heterogeneity (τ2 = 0.159, I2 = 68%). Excluding Montgomery
et al. (2012) not only reduced heterogeneity (τ2 = 0.053, I2 =
43%) but also reduced the effect size from SMD= − 0.49 (95%
CI; − 0.90 to − 0.08) to SMD= − 0.31 (95% CI; − 0.63 to −
0.004).
Four studies compared a cannabis-using group (total n =
88) with healthy controls (total n = 71), on a time-based PM
task. There was a moderate combined effect size, with the
cannabis groups performing worse, and no heterogeneity
(τ2 = 0, I2 = 0%).
Ecstasy
Eight studies compared an ecstasy group (n = 272) with vary-
ing histories of quantities of ecstasy consumed (estimated total
lifetime use ranging between 30 and 668 tablets) with healthy
controls (n = 196), on an event-based PM task, with ecstasy
groups performing worse, displaying a small to large effect.
There was moderate heterogeneity (τ2 = 0.065, I2 = 45%).
Five studies compared an ecstasy group (total n = 213) with
healthy controls (total n = 127), on a time-based PM task, with
ecstasy groups performingworse, which also indicated a small
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to large effect. There was high heterogeneity (τ2 = 0.32, I2 =
80%). Excluding Montgomery et al. (2010) explained the het-
erogeneity (τ2 = 0, I 2 = 0%) and increased the effect size from
SMD = − 0.81 (95% CI; − 1.36 to − 0.26) to SMD= − 1.08
(95% CI; − 1.36 to − 0.809).
Methamphetamine
Two studies compared a methamphetamine group with an
estimated total lifetime use ranging between 720 and 1058 g,
(total n = 59) with healthy controls (total n = 46), on an event-
based PM task, with methamphetamine groups performing
worse, indicating a small to large effect. There was high het-
erogeneity (τ2 = 0.359, I2 = 78%).
The same two studies compared groups on a time-based
PM task, with methamphetamine groups performing worse,
indicating a moderate to large effect size with low heteroge-
neity (τ2 = 0.013, I2 = 12%).
Opiates
One study compared an opiate group (long-term heroin users
enrolled in opioid replacement treatment estimated lifetime
use of 4272 g; n = 26) with controls (n = 30) on an event-
and time-based task, both indicating a moderate to large effect,
with the opiate group performing worse than healthy controls.
Smoked tobacco/nicotine
Seven studies (eight group comparisons) compared a tobacco-
smoking group (total n = 175), with an estimated total lifetime
ranging between 10,610 and 117,511 cigarettes, with healthy
controls (total n = 153), on an event-based PM task. These
indicated that tobacco groups tended to perform worse than
controls, with a moderate to large combined effect and mod-
erate heterogeneity (τ2 = 0.344, I2 = 74%). No study appeared
to explain heterogeneity.
Six studies compared a tobacco group (total n = 111) with
healthy controls (total n = 100), on a time-based PM task,
indicating a negligible-large effect. There was no significant
difference between groups with studies that reported contrast-
ing findings. There was high heterogeneity (τ2 = 1.46, I2 =
91%). Again, no individual study’s removal reduced
heterogeneity.
Meta-regression
Meta-regression analyses revealed an influence of PM task’s
reliability/validity rating (Qmodel (2) = 6.86, p = 0.032, R
2 =
22%). Studies using measures with acceptable test-retest reli-
ability and concurrent validity displayed a large effect size
SMD (k = 8) = − 0.953 95% CI (− 1.404, − 0.502, p < 0.001).
Studies reporting concurrent validity (with objective mea-
sures) and questionable or no evidence of test-retest reliability
or split-half reliability displayed a larger overall effect size
with wider CIs SMD (k = 7) = 1.274 (0.657 to 1.890,
p < 0.001). While tasks with no evidence of psychometric
properties (reliability and validity) displayed smaller effect
sizes SMD (k = 8) = − 0.357 95% CI (− 0.77, − 0.043, p =
0.08). However, this was not observed for the event-based
PM (Qmodel (2) = 1.959, p = 0.367, R
2 = 0%). Categorisation
of lifetime dosage displayed no explanatory value.
Discussion
This study used a meta-analytic approach to examine the mag-
nitude of PM impairments across studies of various licit and
illicit recreational drugs. Our analyses revealed that regular
users of alcohol, cannabis, ecstasy and opiates performed sig-
nificantly worse than controls on event- and on time-based
PM tasks. Regular smokers performed significantly worse
than controls on event-based but not time-based PM tasks,
although the effect size estimate for the latter was particularly
imprecise with the true effect lying between very large (SMD
approximately − 2) and negligible. The effect sizes for impair-
ments on event-based PM tasks were moderate–large in
smokers and heroin users (the latter based on a single study),
small–large for alcohol, ecstasy and methamphetamine use,
and negligible–large for cannabis. Effect sizes for time-based
PM tasks were moderate–large for methamphetamine and opi-
ate use, moderate for cannabis, small–large for ecstasy and
negligible–large for tobacco and alcohol. Heterogeneity influ-
enced a number of effect size estimates. As an illustration of
the effects of individual studies in determining heterogeneity
(as well as overall effect size), exclusion of the study by Platt
et al. (2016), resulted in a marked reduction in the heteroge-
neity of effect sizes in time-based PM performance amongst
studies of heavy drinkers, as well as nearly halving the overall
effect size.
Despite reflecting the effects of chronic/sub-acute sub-
stance use, rather than acute intoxication, the effects
summarised here are broadly in line with laboratory studies
of acute effects of alcohol on PM (Leitz et al. 2009;
Montgomery et al. 2011; Paraskevaides et al. 2010).
However, it is important to note that effects of acute alcohol
have to date only been investigated in light/social drinkers.
The acute-on-chronic effects of alcohol in heavy drinkers have
yet to be investigated. In addition, effects reported here on
ecstasy (unverifiedMDMAcontent) are similar to those found
following acute MDMA administration in laboratory settings
(Kuypers et al. 2013; Ramaekers et al. 2009; van Wel et al.
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2011). In contrast to the effects of smoked tobacco/nicotine
reported here, laboratory-based studies on the acute effects of
nicotine have found nicotine to improve PM performance of
smokers (Dawkins et al. 2013; Jansari et al. 2013; Rusted et al.
2005; Rusted and Trawley 2006) and ‘non-smokers’ (Rusted
and Trawley 2006), with the exception of one study showing
no effect of nicotine on PM in never-smokers (Jansari et al.
2013).
A number of methodological issues were identified within
the reviewed studies. For example, there was a high level of
polydrug use across studies, particularly in the ecstasy studies.
This highlights the difficulty of distinguishing discrete drug
effects in studies of non-acutely intoxicated users.
Specifically, it is unclear to what extent the observed impair-
ments were due to the primary drug of interest versus other
regularly used drugs, or indeed the combination of drugs. In
studies of smokers for instance, participants had high levels of
alcohol use, some reaching levels as high as those reported in
the studies of heavy drinkers. The lack of comprehensive
reporting on general drug use in many studies makes it diffi-
cult to ascertain the true effect of polydrug use on the effects
reported here. In addition, since assessment of bias relating to
drug use in the previous 24 h was ‘unclear’ in most studies, the
role of abstention (or withdrawal) or acute drug effects in the
impairments reported here also remains unclear. Related con-
founds also complicate interpretation. For example, Ludicello
et al. (2011) reported high prevalence of AIDS in their sample
of methamphetamine users (60%) introducing two potential
confounds; the cognitive impairment of HIV/AIDS (Watkins
and Treisman 2015) and the possible effects of antiretroviral
therapy on cognitive performance (Liner et al. 2008).
Many studies had recruited participants from student pop-
ulations. Higher levels of education and/or cognitive ability
(intelligence) in the drug-using groups may have protected
against the cognitive impairing effects of drug use (in line with
a cognitive reserve hypothesis) and contribute to some of the
smaller effect sizes found in the meta-analyses. Other studies
recruited their drug-using groups from outside student subject
pools and in clinical settings or detox treatment (e.g. Bedi and
Redman 2008b; Griffiths et al. 2012; Terrett et al. 2014;
Weinborn et al. 2011). For example, Griffiths and colleagues
recruited their experimental group from a residential sub-
stance misuse service for those with alcohol dependence,
and their control group from a university subject pool
consisting of students and members of the public. These stud-
ies might have greater clinical relevance but they also have a
potential for greater bias, associated with for example, the
presence of comorbid psychiatric disorders (Hasin et al.
2007) and lower socioeconomic status (Hackman et al.
2010) in more severely affected drug users found in clinical
settings. For example, schizophrenia is associated with greater
PM impairments than affective disorders (Burton et al. 2018).
By recruiting comparison groups from the same or similar
populations, matching groups on relevant demographics
(e.g. age, educational achievement, premorbid IQ) and using
conservative inclusion criteria, future research should aim to
increase the internal and external validity of studies.
Surprisingly, lifetime drug dose did not appear to moderate
the size of PM impairments. This may have been a result of the
relatively crude categorical rating scheme used here, as life-
time dose is a continuous variable. However, this was chosen
given the variance in reporting methods on quantifiable drug
use. An alternative categorical rating scheme might have been
more informative, examining the moderating influence of reg-
ularity of drug use (e.g. daily versus less regular use).
Moderation analyses within each drug group might have been
more informative in determining the moderating role of life-
time drug dose, since cumulative neurotoxicity may be more
severe for some drugs (e.g. alcohol and methamphetamine)
than others (e.g. smoked tobacco). However, given the small
number of studies per drug grouping, such an analysis would
have been underpowered.
In most studies, participants were allocated to groups with
un-validated measures of drug use. The exception was
Weinborn et al. (2011) and Platt et al. (2016). In these studies,
a cut-off score on a validated measure of alcohol use was used
for group allocation. However, no further verification of drug/
alcohol use was used and as such, healthy controls may have
under-reported the quantity and frequency of drug/alcohol use
(e.g. see Townshend and Duka 2002). Such under-reporting
might have reduced the differences in mean PM performance
between control and drug-using groups.
There are a number of limitations inherent in the present
review. First, as already noted, the number of studies per drug
class was relatively small, which may have adversely affected
the precision of effect size estimates. Second, different mea-
sures of PM were used across the different studies, with some
measures having limited evidence of adequate psychometric
properties. Thirdly and relatedly, the effect sizes were
characterised bymoderate to high levels of heterogeneity, lim-
iting the strength of conclusions about true effect sizes.
Fourthly, we limited the inclusion of studies to those covering
relatively common drugs associated with problematic use.
Other major drug classes, including various novel psychoac-
tive substances that are known to have cognitive impairing
effects, were not examined.
Summary
In studies of non-acutely intoxicated recreational drug users,
PM impairments were found in all drug-using groups (heavy
drinkers, smokers, and cannabis, ecstasy, methamphetamine
or opiate users). However, there were no prospective studies
on drug use and PM deficits with a parallel group design, and
as such it remains unclear whether PM deficits are a risk factor
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for or consequence of recreational drug use. A number of
methodological limitations/sources of bias were identified in
most studies. Furthermore, there were high levels of method-
ological and effect size heterogeneity across studies which
limit the strength of conclusions that can be drawn about the
true effect size of PM impairments for different drugs. Future
studies should seek to address the identified methodological
issues and also investigate the effects of different patterns of
recreational drug use on event and time PM tasks of differing
demand levels.
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